Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study.
about
Cancer immunotherapy: moving beyond current vaccinesTherapeutic cancer vaccines: using unique antigensHeat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of CancerPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerHeat shock proteins: stimulators of innate and acquired immunityTherapeutic cancer vaccines: past, present, and futureHeat shock protein vaccines against glioblastoma: from bench to bedsideAutologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.Identification of peptide mimotopes of gp96 using single-chain antibody library.Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice.HSPs drive dichotomous T-cell immune responses via DNA methylome remodelling in antigen presenting cells.Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implicationsInduction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cellsHeat shock proteins: the fountainhead of innate and adaptive immune responses.Lung cancer immunotherapy.Hsp70 interactions with the p53 tumour suppressor protein.Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency.Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors.HSPPC-96: a personalised cancer vaccine.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Heat-shock protein-based vaccines for cancer and infectious disease.Vitespen: a preclinical and clinical review.Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice.Novel therapeutic agents under investigation for malignant melanoma.Chaperone proteins and brain tumors: potential targets and possible therapeutics.Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation.Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.Trial watch: Peptide vaccines in cancer therapyTherapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cellsVaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findingsPromises and limitations of murine models in the development of anticancer T-cell vaccines.Heat shock protein vaccines: from bench to bedside.Emerging microfluidic tools for functional cellular immunophenotyping: a new potential paradigm for immune status characterization.Heat-shock protein-peptide complex-96 for the treatment of cancer.Phenotypically distinct helper NK cells are required for gp96-mediated anti-tumor immunity.Vaccine therapy for renal cancer.Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity
P2860
Q24548229-E47630FC-5FE9-47F9-896C-1D2B6C49B7B5Q24563772-0A47F26F-2ACE-4D1F-B77C-D20D128454D3Q26747392-68833F8C-6422-4671-948C-036317AD077CQ26795466-96A04FEC-E484-47BB-B172-3B27D065DD54Q26829100-7C393AF6-792D-4C16-8AC7-BC5CB1214ADAQ26863283-01E15334-BAE6-4A73-8DAB-7BF47870509BQ28087775-35C4C6B2-C3B2-44FB-A510-2029DBB2C693Q33527158-96A01DA4-E765-494A-951F-69CE933EF883Q33720789-836C9642-0E58-4E1F-88C9-1A11E94B1799Q33730763-9D48E0D2-983B-4997-ABC6-1FCD87800793Q33766735-D21B716C-592A-41E4-B0D4-161C0B9AE60AQ33899708-B222E94C-F4FC-4F57-B67E-30799BFBE604Q34024223-9C5B8A0D-EB97-4AF2-8B10-9DDAAD73919FQ34145113-5D86E98A-28B0-4381-B7A1-033A58C77EFCQ34146503-E3DC080D-3F1C-4545-84FB-6F4E69598A28Q34353830-E1FC296E-1CD3-46D3-8639-7A1C83F9411EQ34382810-E83C361C-E95B-4F7A-8115-711EDF06A2A4Q34451153-9B2F324D-A226-473E-84F1-1175FE139A1BQ34452027-408A9C31-31CC-4DAC-B05C-A18DCD50CD9BQ34669820-59198C1D-7571-42AE-88FA-9FAD87AEF916Q34768299-BF38F523-9CEA-475D-91FD-63A9F23F630FQ34996187-E806E096-98FB-4EC1-94DD-AF6848BBA3F0Q35010256-4F9D6B09-CBB4-49B4-9AAF-C626766374A0Q35207632-5A3EA753-F09C-4669-8A06-86821DDA7025Q35800492-5915EE1F-98ED-4287-9720-5831AC17294BQ36134014-B21842AE-9F0C-4250-BB6E-9CC68CCAE6C1Q36235551-E89F1076-1408-4CCE-9A23-A12134148640Q36239656-75DEAA7E-F2EF-4448-909D-F3249255F092Q36476100-E0A54975-E7F4-4F7C-8200-3334FC4A2FAFQ36499222-E7830BF5-2235-4220-AC8F-FA3AC4910FA6Q36509697-09396ABC-7301-49A2-BBFA-B2356463DA9DQ36615603-7584F949-A1BC-486B-BE1C-E97648660D95Q36684482-3CD6449B-E444-4B07-85CD-6CA57632635EQ36684490-37810F00-6B2C-401E-BF60-47C67C5E895DQ36782417-96466745-DA3E-4753-A1B7-51FDF378F177Q36909395-70C81771-8928-4908-A9B8-F176D5D2355AQ37104984-A4729646-394B-4882-AA3A-0379A87638ACQ37259586-46DDCB9C-7D90-42E6-AEC1-4E56B6E3A918Q37412334-7DC25D0F-2A22-46BD-A8BB-6498373D8730Q37461025-5F64758D-D37B-4E42-9F8E-851E677EBE64
P2860
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Immunization of cancer patient ...... 6 preparations: a pilot study.
@en
type
label
Immunization of cancer patient ...... 6 preparations: a pilot study.
@en
prefLabel
Immunization of cancer patient ...... 6 preparations: a pilot study.
@en
P2093
P2860
P1476
Immunization of cancer patient ...... 6 preparations: a pilot study.
@en
P2093
P K Srivastava
S Janetzki
V Rosenhauer
P2860
P304
P356
10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8
P577
2000-10-01T00:00:00Z